Reported Late Thursday, March 2, Terns Pharmaceuticals’ Program Updates; Q3 Adjusted Cash Balance As Of Sept 30, 2022, Of $293M Provides Cash Runway Into 2026
Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in the third quarter of 2023
On track to initiate U.S. clinical trial